Cancer Center, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, China.
Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, P.R. China.
Curr Med Chem. 2020;27(34):5716-5729. doi: 10.2174/0929867326666190618161610.
Immunotherapy for cancer includes Chimeric Antigen Receptor (CAR)-T cells, CAR-natural Killer (NK) cells, PD1, and the PD-L1 inhibitor. However, the proportion of patients who respond to cancer immunotherapy is not satisfactory. Concurrently, nanotechnology has experienced a revolution in cancer diagnosis and therapy. There are few clinically approved nanoparticles that can selectively bind and target cancer cells and incorporate molecules, although many therapeutic nanocarriers have been approved for clinical use. There are no systematic reviews outlining how nanomedicine and immunotherapy are used in combination to treat cancer.
This review aims to illustrate how nanomedicine and immunotherapy can be used for cancer treatment to overcome the limitations of the low proportion of patients who respond to cancer immunotherapy and the rarity of nanomaterials in clinical use.
A literature review of MEDLINE, PubMed / PubMed Central, and Google Scholar was performed. We performed a structured search of literature reviews on nanoparticle drug-delivery systems, which included photodynamic therapy, photothermal therapy, photoacoustic therapy, and immunotherapy for cancer. Moreover, we detailed the advantages and disadvantages of the various nanoparticles incorporated with molecules to discuss the challenges and solutions associated with cancer treatment.
This review identified the advantages and disadvantages associated with improving health care and outcomes. The findings of this review confirmed the importance of nanomedicinecombined immunotherapy for improving the efficacy of cancer treatment. It may become a new way to develop novel cancer therapeutics using nanomaterials to achieve synergistic anticancer immunity.
癌症的免疫疗法包括嵌合抗原受体（CAR）-T 细胞、CAR-自然杀伤（NK）细胞、PD1 和 PD-L1 抑制剂。然而，对癌症免疫疗法有反应的患者比例并不令人满意。同时，纳米技术在癌症的诊断和治疗方面经历了一场革命。虽然有许多治疗性纳米载体已被批准用于临床使用，但能够选择性结合和靶向癌细胞并结合分子的临床批准的纳米颗粒很少。目前还没有系统的综述来描述纳米医学和免疫疗法如何联合用于治疗癌症，以克服癌症免疫疗法反应率低和纳米材料临床应用罕见的局限性。
本综述旨在说明如何将纳米医学和免疫疗法联合用于癌症治疗，以克服癌症免疫疗法反应率低和纳米材料临床应用罕见的局限性。
对 MEDLINE、PubMed/PubMed Central 和 Google Scholar 进行了文献回顾。我们对纳米药物传递系统的文献综述进行了结构化搜索，其中包括光动力疗法、光热疗法、光声疗法和癌症的免疫疗法。此外，我们详细讨论了各种与分子结合的纳米颗粒的优缺点，以探讨与癌症治疗相关的挑战和解决方案。
本综述确定了改善医疗保健和结果的优缺点。本综述的结果证实了纳米医学联合免疫疗法在提高癌症治疗效果方面的重要性。它可能成为利用纳米材料开发新型癌症治疗方法以实现协同抗癌免疫的新途径。
